<DOC>
	<DOCNO>NCT02627820</DOCNO>
	<brief_summary>ATTRwt ( also know senile systemic , senile cardiac amyloidosis ) progressive heart disease , cause congestive heart failure . It cause amyloid protein deposit heart , derive normal protein , TTR , make liver . The aim study determine whether lower blood level TTR , weekly injection compound design specifically , slow progression disease treat patient compare previously-followed patient receive drug . The study also aim determine well drug tolerate existence severity drug side-effects .</brief_summary>
	<brief_title>The Effect Antisense Oligonucleotide Lower Transthyretin ( TTR ) Levels Progression -Wild-type TTR Involving Heart</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>All patient document SSA consider inclusion . SSA define echocardiographic appearance leave ventricular wall thickness 13 mm , absence uncontrolled hypertension , positive biopsy amyloid , also stain positive TTR immunochemistry mass spectrometry . For definition SSA , genetic test negative mutation . Identification amyloid type standard care patient see Cardiac Amyloidosis Program presence clinically obtain positive biopsy requirement study inclusion . The positive biopsy organ , provide echocardiographic appearance typical amyloidosis . 1 . Patients , opinion Investigator , stable state term NYHA class . Class IIII patient recruit . 2 . Age 5090 year 3 . Male nonpregnant , nonlactating female . If woman premenopausal , male partner premenopausal woman , she/he must willing use follow method contraception : condom , oral/hormonal contraception , Intrauterine Device , diaphragm , abstinence 4 . Written inform consent obtain prior study treatment 5 . Histochemical diagnosis amyloidosis base detection polarize microscopy green birefringent material Congo redstained tissue specimens 6 . Molecular definition absence TTR mutation immunohistochemical staining amyloid fibrils anti TTR antibody negative genetic test TTR mutation . 7 . Willingness return treat center followup . 8 . Willingness ability selfadminister , spouse administer weekly subcutaneous injection study drug . 1 . Patients , opinion Investigator , require adjustment diuretic time screen achieve optimal treatment heart failure . Once stable 2 week , patient Class IIII become eligible inclusion . 2 . Patients NYHA class 4 congestive heart failure . 3 . Concomitant nonamyloid heart disease might , opinion investigator , cause change strain image serial followup ( e.g . aortic stenosis great mild severity , unstable coronary artery disease ) . 4 . Prior liver transplantation liver transplantation anticipate less 6 month ; 5 . ALT and/or AST ³ 2 x ULN and/or Alkaline phosphatase ³ 2 x UNL ; 6 . Estimated glomerular filtration rate ( EGFR ) &lt; 50 ml/min ; 7 . Any lab value opinion investigator might place subject unacceptable risk participation study ; 8 . History poor compliance medication medical treatment , base review medical record . 9 . History hypersensitivity ingredient study therapy ; 10 . Use investigational drug amyloidosis within 4 week prior study entry study . 11 . Current use tafamidis , diflunisal , doxycycline TUDCA therapy amyloidosis .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Senile</keyword>
	<keyword>ATTRwt</keyword>
	<keyword>wild-type transthyretin amyloidosis</keyword>
</DOC>